Black Diamond Therapeutics, Inc.
BDTX
$2.16
-$0.02-0.69%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
3/18/2026
-
MarketBeat
Black Diamond Therapeutics (BDTX) Profit Swing To US$0.81 EPS Challenges Bearish Earnings Narratives
3/18/2026
-
Simply Wall St
3/17/2026
-
MarketBeat
3/17/2026
-
TipRanks Financial Blog
3/17/2026
-
TipRanks Financial Blog
3/16/2026
-
MarketBeat
3/16/2026
-
TipRanks Financial Blog
3/16/2026
-
The Fly
3/16/2026
-
Globe Newswire
3/9/2026
-
Zacks Investment Research
3/6/2026
-
MarketBeat
3/2/2026
-
Globe Newswire
2/26/2026
-
MarketBeat
2/21/2026
-
MarketBeat
2/18/2026
-
MarketBeat
2/11/2026
-
PR Newswire
2/3/2026
-
Ticker Report
2/2/2026
-
Insider Monkey
2/2/2026
-
Yahoo! Finance: News
1/27/2026
-
MarketBeat
1/23/2026
-
Zacks Investment Research
1/16/2026
-
The Fly
1/16/2026
-
MarketBeat
1/10/2026
-
Simply Wall St
1/10/2026
-
Ticker Report
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Thursday, November 6, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Mar 2 and 6 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
617 252 0848
Address
245 First Street
Cambridge, MA 02142
Cambridge, MA 02142
Country
Year Founded
Business Description
Sector
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company’s...
more